OCUL
Price
$12.21
Change
-$0.31 (-2.48%)
Updated
Aug 29 closing price
Capitalization
2.12B
71 days until earnings call
RCUS
Price
$10.59
Change
-$0.02 (-0.19%)
Updated
Aug 29 closing price
Capitalization
1.13B
72 days until earnings call
Interact to see
Advertisement

OCUL vs RCUS

Header iconOCUL vs RCUS Comparison
Open Charts OCUL vs RCUSBanner chart's image
Ocular Therapeutix
Price$12.21
Change-$0.31 (-2.48%)
Volume$2.07M
Capitalization2.12B
Arcus Biosciences
Price$10.59
Change-$0.02 (-0.19%)
Volume$548.28K
Capitalization1.13B
OCUL vs RCUS Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. RCUS commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Buy and RCUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (OCUL: $12.21 vs. RCUS: $10.59)
Brand notoriety: OCUL and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 96% vs. RCUS: 67%
Market capitalization -- OCUL: $2.12B vs. RCUS: $1.13B
OCUL [@Biotechnology] is valued at $2.12B. RCUS’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both OCUL and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 2 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 2 bullish, 5 bearish.
  • RCUS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а -0.73% price change this week, while RCUS (@Biotechnology) price change was +0.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.12B) has a higher market cap than RCUS($1.13B). OCUL YTD gains are higher at: 42.974 vs. RCUS (-28.878). OCUL has higher annual earnings (EBITDA): -200.5M vs. RCUS (-282M). RCUS has more cash in the bank: 911M vs. OCUL (391M). OCUL has less debt than RCUS: OCUL (76.9M) vs RCUS (109M). RCUS has higher revenues than OCUL: RCUS (262M) vs OCUL (56.7M).
OCULRCUSOCUL / RCUS
Capitalization2.12B1.13B188%
EBITDA-200.5M-282M71%
Gain YTD42.974-28.878-149%
P/E RatioN/AN/A-
Revenue56.7M262M22%
Total Cash391M911M43%
Total Debt76.9M109M71%
FUNDAMENTALS RATINGS
OCUL vs RCUS: Fundamental Ratings
OCUL
RCUS
OUTLOOK RATING
1..100
6731
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3953
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
1950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (49) in the Pharmaceuticals Major industry is in the same range as OCUL (54) in the Pharmaceuticals Other industry. This means that RCUS’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (84) in the Pharmaceuticals Other industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that RCUS’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as RCUS (53) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that RCUS’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULRCUS
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 24 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWVAX12.61N/A
N/A
Hotchkis & Wiley Sm Cp Divers Val A
TSFYX15.29-0.04
-0.26%
Touchstone Small Cap Y
DISVX29.40-0.08
-0.27%
DFA International Small Cap Value I
PFSVX14.68-0.06
-0.41%
iMGP Small Company Fund Instl Cl
FMIUX39.93-0.17
-0.42%
FMI Common Stock Institutional

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-2.48%
EYPT - OCUL
65%
Loosely correlated
-0.26%
CRNX - OCUL
55%
Loosely correlated
+1.11%
RVMD - OCUL
55%
Loosely correlated
-0.93%
IDYA - OCUL
55%
Loosely correlated
-1.52%
DNLI - OCUL
54%
Loosely correlated
-2.43%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-0.19%
XNCR - RCUS
51%
Loosely correlated
+0.99%
CRNX - RCUS
50%
Loosely correlated
+1.11%
TRDA - RCUS
49%
Loosely correlated
-3.19%
MNMD - RCUS
49%
Loosely correlated
-9.20%
IDYA - RCUS
48%
Loosely correlated
-1.52%
More